Does immunodeficiency in uremic patients promote dialysis-related amyloidosis?
The present study was undertaken to evaluate the immune function of 5 hemodialysis patients with dialysis-related amyloidosis as compared to 6 without, both groups having a dialytic age from 7 to 21 years, and 5 healthy controls. We investigated serum levels of immunoglobulins (IgG, IgA, IgM), made skin tests and measured peripheral lymphocyte subsets using monoclonal antibodies. 1) The absolute numbers of T3, T4 and T8 cells were significantly lower in hemodialysis patients than controls and T3, T4 cells were lower in patients with amyloidosis than in those without: T3 (m +/- SD/microliter), 387 +/- 253 vs 744 +/- 207 (p = 0.03); T4, 262 +/- 115 vs 589 +/- 297 (p = 0.04). 2) Serum levels of IgG and IgM were significantly lower in patients with amyloidosis than in the others: IgG (m +/- SD, g/l), 10.2 +/- 1.4 vs 15.4 +/- 3.2 (p less than 0.001); IgM, 0.65 +/- 0.28 vs 1.65 +/- 0.37 (p less than 0.001). 3) Delayed hypersensitivity studied by skin tests showed less than 3 positive antigens in 4/5 patients with amyloidosis against 1/6 patients without. These data suggest there is a marked defect of T-cell help in uremic patients with dialysis-related amyloidosis.
Simon
P
P
Department of Nephrology La Beauchée Hospital, Saint-Brieuc, France.
Ang
K S
KS
Cavarle
Y
Y
Cam
G
G
Catheline
M
M
Genetet
N
N
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000209:etiology*; D004406:Dysgammaglobulinemia / Q000276:immunology*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D017099:IgG Deficiency; D007075:Immunoglobulin M / Q000172:deficiency*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D012882:Skin Tests; D013601:T-Lymphocytes / Q000145:classification*; D014511:Uremia / Q000276:immunology* / Q000628:therapy
D007075:Immunoglobulin M